Simulations Plus (NASDAQ:SLP) Stock Passes Above 200-Day Moving Average – Should You Sell?

Simulations Plus, Inc. (NASDAQ:SLP) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $15.56 and traded as high as $18.27. Simulations Plus shares last traded at $18.15, with a volume of 632,074 shares.

Analysts Set New Price Targets

SLP has been the subject of several research reports. Weiss Ratings upgraded shares of Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, June 5th. TD Cowen reduced their target price on shares of Simulations Plus from $19.00 to $16.00 and set a “hold” rating on the stock in a report on Friday, April 10th. William Blair cut shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 17th. Craig Hallum downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price target for the company. in a report on Thursday, June 18th. Finally, Wall Street Zen lowered Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. One equities research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $20.90.

Simulations Plus Stock Performance

The company has a fifty day moving average of $15.54 and a two-hundred day moving average of $15.56. The company has a market cap of $366.63 million, a PE ratio of -5.80 and a beta of 1.33.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Thursday, April 9th. The technology company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.08. The company had revenue of $24.29 million during the quarter, compared to the consensus estimate of $21.66 million. Simulations Plus had a positive return on equity of 16.21% and a negative net margin of 77.96%. On average, equities analysts forecast that Simulations Plus, Inc. will post 0.8 EPS for the current year.

Hedge Funds Weigh In On Simulations Plus

A number of large investors have recently made changes to their positions in SLP. First Light Asset Management LLC boosted its stake in shares of Simulations Plus by 156.4% during the 4th quarter. First Light Asset Management LLC now owns 1,968,917 shares of the technology company’s stock worth $35,893,000 after purchasing an additional 1,201,157 shares during the period. First Eagle Investment Management LLC raised its position in Simulations Plus by 1,898.1% in the 4th quarter. First Eagle Investment Management LLC now owns 457,155 shares of the technology company’s stock worth $8,334,000 after purchasing an additional 434,275 shares during the period. Meros Investment Management LP purchased a new stake in Simulations Plus in the 4th quarter worth about $6,184,000. Marshall Wace LLP lifted its stake in Simulations Plus by 127.5% in the fourth quarter. Marshall Wace LLP now owns 569,783 shares of the technology company’s stock worth $10,387,000 after purchasing an additional 319,301 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Simulations Plus by 278.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 427,865 shares of the technology company’s stock worth $7,800,000 after purchasing an additional 314,844 shares during the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.